A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Carcinoma, Non-Small-Cell Lung
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 103 (final count)
- Started
- Apr 4, 2024
- Main results expected
- Oct 27, 2026
- Fully finished
- Jan 5, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) in randomized participants
Measured over: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
PFS at 6 months
Measured over: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
PFS at 12 months
Measured over: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06008093 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC